Michael Mauro, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, discusses unmet needs in pediatric chronic myeloid leukemia (CML), including the need to better define the role of transplantation and available tyrosine kinase inhibitors (TKIs), as well as improving therapy adherence and getting more patients into treatment-free remission (TFR), and better understanding the role of measurable residual disease (MRD) in this patient population. This interview took place at the 24th Annual John Goldman Conference on Chronic Myeloid Leukemia (ESH CML) held in Mandelieu-La Napoule, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Research funding: Novartis, Bristol Myers Squibb, Sun Pharma/Sparc, Takeda; consultancy: Novartis, Bristol Myers Squibb, Takeda, Pfizer.